Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
-0.37%
)
US TECH 100
23,546.80
(
0.11%
)
Dow Jones
46,124.06
(
-0.18%
)
Brent Oil
96.18
(
-0.34%
)
Bitcoin
70,817.00
(
0.42%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 87877

Monday, 12/21/2009 8:28:57 AM

Monday, December 21, 2009 8:28:57 AM

Post# of 257275
Designating the $30M as R&D reimbursement is a transparent attempt to circumvent the ISIS pass-through. This is the second or third time I’ve seen such a maneuver in a biotech license; I doubt it could stand up to legal challenge, but Teva and OGXI may figure the amount is too small for ISIS to bothering suing.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today